Skip navigation
RSS feed for this page
Know something we don't? Submit a conference announcement
Choose Category:

Novel Therapies meetings & conferences

9 meetings & conferences listed in Novel Therapies 

Eleventh International Kawasaki Disease Symposium
United States

Eleventh International Kawasaki Disease Symposium

Feb. 3-6, 2015 Honolulu, Hawaii

This 3 ½ day conference includes lectures, discussions, and oral/poster presentations focusing on the latest advances in Kawasaki disease. Kawasaki disease is the major cause of acquired childhood heart disease in developed countries. Children who develop significant coronary artery aneurysms as a result of Kawasaki disease have a lifetime increased risk of myocardial ischemia, infarction, and sudden death. The study of Kawasaki disease and its treatment are likely to yield important answers to general questions in cardiovascular health and disease that apply equally to pediatric and adult populations.

The Eleventh International Kawasaki Disease Symposium seeks to address the influence of genetics on disease susceptibility and outcomes, the mechanisms of coronary artery damage following severe acute inflammation, the role of immune modulation and other novel therapies in preventing artery damage, the potential use of serum biomarkers for diagnosis and prognosis, the use of newer imaging techniques to assess abnormalities of the coronary arteries and myocardium, and new therapies regarding anticoagulation and vascular health. Current data regarding the worldwide epidemiology will be highlighted, as well as psychosocial issues, guidelines and nursing practice .

Since the historic first International Kawasaki Disease Symposium in 1984, the international symposium has been held every 3 years in Japan, the United States, or Taiwan, drawing attendees from all continents.

Who Should Attend -  The audience will consist of pediatric and adult cardiologists, pediatricians and pediatric subspecialists in immunology, infectious disease, and rheumatology;  cardiovascular surgeons; pathologists; basic scientists in genetics, molecular biology, microbiology, and cardiovascular pathophysiology; public health officials from county and state agencies and the Center for Disease Control and Prevention; epidemiologists; and nurses working in pediatric cardiology and public health who have an interest in Kawasaki disease.


Summarize prevailing hypotheses regarding KD etiology, and discuss emerging research supporting or contradicting these hypotheses.

Summarize current findings regarding diagnostic and prognostic biomarkers for KD, and their potential significance to clinical practice.

Summarize the most recent research and clinical findings regarding genetic susceptibility to KD and to KD coronary artery disease.

Summarize the most recent research and clinical findings regarding IVIG mechanism of action and the efficacy of additional or alternative therapies

Review evidence regarding the two distinct arterial processes that can lead to myocardial ischemia or infarction.

Review available imaging modalities for their ability to assess for presence of thrombosis and luminal myofibroblastic proliferation.

Summarize technical principles and current evidence supporting use of various imaging modalities in determining KD prognosis and optimal long-term follow-up.

Review evidence regarding the efficacy, safety, and long-term expected outcomes of revascularization options for KD patients.

Review current understanding, recent findings, and unresolved issues regarding optimization of thromboprophylaxis in KD patients.

Cardiologist, Cardiothoracic Surgeon, Epidemiologist, Microbiologist, Molecular Biologist, Pathologist, Patient, Pediatrician, Public Health Expert, Public Health Worker, Surgeon
7th Clinical Trials on Alzheimer’s Disease
United States

7th Clinical Trials on Alzheimer’s Disease

November 20-22, 2014 Philadelphia, Pennsylvania

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, predict progression, and assess the effectiveness of new treatments.

The future of clinical trials may lie in the development of combination therapies of two or more drugs. CTAD 2014 will highlight the latest on trying to get these trials off the ground.

Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.

Neurologist, Physician Researcher
Antibiotic Alternatives for the New Millennium
United Kingdom

Antibiotic Alternatives for the New Millennium

Wednesday, 05 November 2014 09:00-Friday, 07 November 2014 17:00 London, United Kingdom

The inexorable rise in the incidence of antibiotic resistance in bacterial pathogens, coupled with the disappointingly low rate of emergence of new,clinically useful antibiotics, has refocused attention on finding alternatives to antibiotic treatments. This event will discuss the potential utility of phages, probiotics, antimicrobial peptides, herbal medicines and immune modulation for treating human and animal disease.

Who Should Attend

From researchers trying to find alternatives to therapies to pharmacists delivering treatments: any one with an interest in antibiotic alternatives would find this event of value.

Clinical Pharmacist, Pharmacist, Pharmacologist, Physician, Physician Researcher, Veterinary Scientist
Targeting VEGF-Mediated Tumor Angiogenesis in Cancer Therapy
United States
New York

Targeting VEGF-Mediated Tumor Angiogenesis in Cancer Therapy

June 19 - 20, 2014 The New York Academy of Sciences

A decade after the first cancer drug targeting VEGF signaling in tumor blood vessel formation received approval by the US Food and Drug Administration (FDA), significant effort has been dedicated toward progressing the research, development, and clinical application of anti-angiogenic cancer therapies.  Drawing on lessons learned from successes and failures, this conference will examine ways to improve cancer therapy by addressing urgent issues such as:

i. inherent /acquired resistance,

ii. immunomodulation,

iii. enhanced invasiveness / metastasis, and

iv. lack of validated predictive and prognostic biomarkers.

Presentations, including a keynote lecture by Harold F. Dvorak, MD, will explore VEGF-dependent and alternative mechanisms of angiogenesis. “Point–Counterpoint” debates between leading experts will aim to resolve controversies regarding the function of vascular normalization, treatment-induced metastasis, and the validity of hypertension as a physiological biomarker.

Oncologist, Physician Researcher
17th Annual Meeting of the American Society of Gene & Cell Therapy
United States
Washington, DC

17th Annual Meeting of the American Society of Gene & Cell Therapy

May 21 – May 24, 2014 Washington, DC

Cell Biologist, Molecular Biologist, Physician Researcher
International Society for Stem Cell Research 12th Annual Meeting

International Society for Stem Cell Research 12th Annual Meeting

June 18-21, 2014 Vancouver, Canada

Bioengineer, Cell Biologist, Molecular Biologist, Physician Researcher, Scientist
Translating Diabetes

Translating Diabetes

Wednesday 30 April - Saturday 3 May 2014 Heidelberg, Germany

This EMBO | EMBL Symposium aims to bring together established experts, physician scientists and basic researchers to discuss the multi-layered and complex processes leading up to novel therapeutic strategies for diabetes, obesity and related health issues, such as cancer and cardiovascular disease.

Endocrinologist, Physician Researcher, Scientist
11th Annual International Symposium of Ultrasound for Regional Anesthesia, Pain Medicine and Perioperative Applications (ISURA)

11th Annual International Symposium of Ultrasound for Regional Anesthesia, Pain Medicine and Perioperative Applications (ISURA)

June 21-24, 2014 Toronto, Canada

The ISURA 2014 scientific program has included distinguished national and international guest faculty and University of Toronto faculty. There will be:

2 days of lectures and hands on workshops for regional anesthesia

2 days for pain medicine and MSK imaging

½ day of cadaver workshop for pain medicine (optional)

2 days for peri-operative application

Both basic and advanced procedures will be discussed. There will be plenty of time for panel discussion, group scanning, and hands on practice on live subjects, pig carcass, and phantom simulators.

By the end of the conference, the participants will be able to:

Describe the basic principles of ultrasound guided regional anesthesia and interventional pain procedures.

Identify proper approaches to image nerve and musculoskeletal structures and insert needle.

Critically interpret images of nerve, vessels and musculoskeletal structures including anatomical variants and artifacts.

Develop the cognitive and practical skills on the use of ultrasound for regional anesthesia and interventional pain procedures.

Develop a practical understanding of MSK imaging for pain evaluation.

Understand the utility of ultrasound for perioperative applications.

All in all, this conference is designed to provide anesthesiologists and pain practitioners a comprehensive review of ultrasound imaging for regional anesthesia, pain medicine (diagnosis and intervention) and perioperative medicine. Our panel of international and national renowned faculty will provide you with the latest developments and state-of-the-art information in the world of ultrasound.

Anesthesiologist, Pain Specialist, Physician, Physician Researcher, Surgeon
16th Biennial Meeting of the European Society for Immunodeficiencies (ESID 2014)
Czech Rep.

16th Biennial Meeting of the European Society for Immunodeficiencies (ESID 2014)

29 October – 1 November, 2014 Prague, Czech Republic

The 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID 2014), being held in the enchanting city of Prague, Czech Republic, offers unparalleled access to the latest research and analysis in the field. Meeting participants will gain valuable insights into innovative perspectives in both basic and clinical research. The scientific programme will draw together experts from around the world to discuss breakthroughs in diagnostic immunology, genetics and immunobiology of human diseases, advances in clinical practice, novel therapeutic approaches to tolerance induction and new insights into stem-cell and cellular therapies.

An ideal forum to share knowledge, connect with professional colleagues and grow your professional network, ESID 2014 is being held 29 October – 1 November, 2014.

Immunologist, Physician, Physician Researcher